PDGFRB
ENSG00000113721
Target class
Kinase
Chromosome
5
Approved drugs
12
Clinical candidates (approved and in development)
42
- Approved drugs
- 12
- Clinical candidates (approved and in development)
- 42
- Chemical probe available
- Yes
- Target name
- PDGFRB
- Gene name
- Platelet derived growth factor receptor beta
- Gene symbol
- PDGFRB
- Previous gene symbols
- PDGFR
- Protein name
- Platelet-derived growth factor receptor beta (PDGF-R-beta) (PDGFR-beta) (EC 2.7.10.1) (Beta platelet-derived growth factor receptor) (Beta-type platelet-derived growth factor receptor) (CD140 antigen-like family member B) (Platelet-derived growth factor receptor 1) (PDGFR-1) (CD antigen CD140b)
- JTK12
- CD140b
- PDGFR1
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|CD molecules|I-set domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 398.15
- Tissue specificity (Gini)
- 0.556
- Tissue specificity (tau)
- 0.767
- KEGG gene identifiers
- hsa:5159
- Protein interaction confidence
- 0.83998
- Protein interaction partners
- 151
- R-HSA-1257604
- R-HSA-186763
- R-HSA-186797
- R-HSA-2219530
- R-HSA-5673001
- R-HSA-6811558
- End position
- 150158260
- Start position
- 150113839
- Chromosome
- 5
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein. Cytoplasmic vesicle. Lysosome lumen. Note=After ligand binding, the autophosphorylated receptor is ubiquitinated and internalized, leading to its degradation.
- Golgi apparatus
- Vesicles
- Tissue specificity (tau)
- 0.76668
- Expression inequality (Gini)
- 0.556031
Expression in transcripts per million
- Cervix - Ectocervix
- 398.15
- Cervix - Endocervix
- 353.6
- Artery - Tibial
- 346.19
- Adipose - Subcutaneous
- 303.23
- Artery - Coronary
- 277.75
Expression in transcripts per million
- Cervix - Ectocervix398.15
- Cervix - Endocervix353.6
- Artery - Tibial346.19
- Adipose - Subcutaneous303.23
- Artery - Coronary277.75
- Artery - Aorta273.44
- Cells - Cultured fibroblasts256.81
- Uterus245.58
- Fallopian Tube217.97
- Ovary210.61
- Adipose - Visceral (Omentum)187.13
- Nerve - Tibial183.26
- Lung182.71
- Breast - Mammary Tissue182.18
- Vagina163.28
- Thyroid141.71
- Bladder103.82
- Prostate101.61
- Esophagus - Gastroesophageal Junction97.89
- Skin - Sun Exposed (Lower leg)96.09
- Esophagus - Muscularis91.51
- Colon - Sigmoid68.57
- Spleen65.29
- Skin - Not Sun Exposed (Suprapubic)55.56
- Small Intestine - Terminal Ileum54.68
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0008284
- GO:0014911
- GO:0018108
- GO:0030335
- GO:0035791
- GO:0038091
- GO:0046777
- GO:0048008
- GO:0048661
- GO:0050850
- GO:0051897
- GO:0060326
- GO:0070374
- GO:0005886
- GO:0005925
- GO:0016020
- GO:0004672
- GO:0004713
- GO:0004992
- GO:0005017
- GO:0005019
- GO:0005096
- GO:0005102
- GO:0005161
- GO:0005515
- GO:0019899
- GO:0019901
- GO:0038085
- GO:0048407
- GO:0160185
heart disease
Studies
- preclinical: Highly important for the heart and vasculature based on findings in genetically modified or kinase-inhibitor-treated mice. Role of kinase in heart/vasculature: β isoform is crucial in angiogenesis and heart’s response to pressure overload
Biological samples
- cardiovascular system
PubMed 21283106
Related records
Trials (3,291)
- "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
- [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- [68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
- [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
- 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
- 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
- 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
- 18F-DCFBC PET/CT in Prostate Cancer
- 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
- 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
- 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Drugs (50)
- Becaplermin Platelet-derived growth factor receptor agonist
- Catequentinib Platelet-derived growth factor receptor beta inhibitor
- CDP-860 Platelet-derived growth factor receptor beta inhibitor
- Cediranib Platelet-derived growth factor receptor inhibitor
- CEP-2563 Platelet-derived growth factor receptor beta inhibitor
- Cep-2563 dihydrochloride Platelet-derived growth factor receptor beta inhibitor
- CM-082 Platelet-derived growth factor receptor beta inhibitor
- Crenolanib Platelet-derived growth factor receptor inhibitor
- Dasatinib anhydrous Platelet-derived growth factor receptor beta inhibitor
- Dovitinib Platelet-derived growth factor receptor inhibitor
- ENMD-981693 Platelet-derived growth factor receptor inhibitor
- Famitinib Platelet-derived growth factor receptor inhibitor
- Foretinib Platelet-derived growth factor receptor inhibitor
- Ilorasertib Platelet-derived growth factor receptor inhibitor
- Imatinib Platelet-derived growth factor receptor beta inhibitor
- Imatinib mesylate Platelet-derived growth factor receptor beta inhibitor
- JI-101 Platelet-derived growth factor receptor beta inhibitor
- Linifanib Platelet-derived growth factor receptor inhibitor
- Masitinib Platelet-derived growth factor receptor inhibitor
- Midostaurin Platelet-derived growth factor receptor inhibitor